Trial Profile
Multicenter, open-label, uncontrolled clinical study of STM-279 in patients with adenosine deaminase (ADA) deficiency (Phase III clinical study)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Elapegademase (Primary)
- Indications Adenosine deaminase deficiency
- Focus Adverse reactions; Therapeutic Use
- Sponsors Teijin Pharma
- 30 Jul 2014 New trial record